Frequently Asked Questions

Yes, ERA test is reproducible and does not change over a long period of time (1–2 years). It need not be repeated in the event of a delay in treatment.

ERA test greatly increases the chances of having a successful pregnancy in coupleswith repeated implantation failure The invasive nature of the test, the need for embryo vitrification and higher cost are some of its limitations.

The test is performed in the secretory phase of either a natural cycle or a hormone replacement (HRT) cycle. This is called mock cycle as the treatment has to mimic the same way during the treatment cycle.

It is indicated for patients with 1) Previous implantation failures despite easy transfer of good quality embryos each time, healthy looking endometrium and easy embryo transfer. 2) Adenomyosis, endometriosis, and chronic endometritis can prove beneficial, as these conditions are associated with an altered ER. 3) Persistent thin or thick endometrium is also an indication for carrying out ERA.

The endometrium is the lining the interior of the uterus where the embryo implants and resides during pregnancy. The endometrium is receptive when it is ready for embryo implantation.

The endometrium is receptive when it is ready for embryo implantation. This period of receptivity is called the window of implantation. Defining a receptive window would avoid embryo wastage and emotional, physical, and financial distress. 3 in every 10 women have a displaced window of implantation.

ERA is the first diagnostic test that determines each woman's unique personalized embryo transfer timing, therefore synchronizing the embryo transfer with the individualized window of implantation. The ERA test evaluates the functioning of the genes that determine the receptivity of the endometrium In the clinical setting, ERA definitely has a place in RIF where endometrial factor could be the contributory cause in less than a quarter of the patients